Intended Audience:
This webcast is designed for all physician specialists and primary care providers
who manage patients with urinary tract disorders, especially those with overactive
bladder and related conditions. These clinical disciplines include, but are not
limited to: urological specialists, specialists in urologic gynecology, primary
care physicians, geriatricians, long-term care directors, women’s health specialists,
nurse practitioners, geriatric nurse practitioners, pharmacists and physician assistants
Registration:
Enrollment for this course is complimentary, and clinicians are invited
to participate in this CME-certified webcast and/or share this invitation
with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support:
Supported by an independent educational grant from Esprit Pharmaceuticals
Designation of Credit:
This activity has been planned and implemented in accordance with the Essentials and Standards
of the Accreditation Council for Continuing Medical Education (ACCME) through the joint
sponsorship of the University of Massachusetts Medical School (UMMS). The UMMS is accredited
by ACCME to provide continuing medical education for physicians.
The UMMS designates this continuing medical education activity for up to 3 credit hours in
Category 1 toward the Physicians Recognition Award of the American Medical Association. Each
physician should claim only those hours of credit that he/she actually spent in the educational
activity.
Statement of Disclosure:
In accordance with the Standards of the Accreditation Council for Continuing Medical Education
(ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the
policy of the University of Massachusetts Medical School to disclose whatever interest or
affiliation a speaker might have with any commercial organization whose products or services
are related to the subject matter being presented.
Faculty Disclosures:
Program Faculty
David R. Staskin, MD
Program Moderator
Associate Professor of Urology
Director, Female Urology and Voiding Dysfunction
Weill Medical College of Cornell University
New York, NY
Grant Support: Indevus
Consultant/Speaker: Pfizer, Glaxo, Astellas, Watson, Indevus, Esprit, Novartis, Ortho-McNeil, American Medical Systems
Norman Zinner, MD, MS, FACS
Medical Director, Western Clinical Research, Inc
Clinical Associate Professor of Urology/Surgery
UCLA School of Medicine
Torrance, CA
Grant: Indevus, Pfizer, Novartis
Consultant: Indevus, Esprit, Novartis, Pfizer, Ortho-McNeil
Speaker's Bureau: Esprit, Pfizer
Kristene Whitmore, M.D.
Director, Pelvic and Sexual Health Institute
at Graduate Hospital
Clinical Associate Professor of Urology
Drexel University
Philadelphia, PA
Consultant/Speaker: Lilly/BI, Ortho-McNeil, Pfizer, Astellas
Advisor: Boston Scientific, Lilly/BI, Medtronic, Ortho-McNeill
Researcher: Boston Scientific, Lilly/BI, Medtronic, Ortho-McNeill, Astellas, Pfizer, Vivus, Advanced Bionics
Educational Objectives:
-
Urologists, gynecologists, primary care physicians, geriatricians, and women’s
health specialists will learn to screen patients for urinary tract disorders,
including overactive bladder, bladder dysfunction, and sub clinical urinary
tract infection.
-
Urologists, gynecologists, primary care physicians, geriatricians, and women’s
health specialists will learn how to confirm the diagnosis of overactive bladder,
and learn the appropriate sequence and use of diagnostic modalities used to confirm
the diagnosis.
-
Urologists, gynecologists, primary care physicians, geriatricians, and women’s health
specialists will learn evidence-based approaches to managing urinary tract, with a
special focus on differentiating safety, efficacy, and pharmacologic properties of
available therapeutic agents.
-
Clinicians will learn how to counsel patients with overactive bladder and guide
them in measures that improve long-term urinary tract health.
-
Clinicians will learn how to implement a systematic approach to diagnostic assessment
of patients with urinary frequency, urgency, and related symptoms.
-
Clinicians will learn how landmark trials and analyses focusing on overactive
bladder should guide pharmacologic therapy.
Copyright (c) 2006 All rights reserved including
